Trial Profile
A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients With Plasma Cell Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 27 Jun 2019 Status changed from active, no longer recruiting to completed.
- 29 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
- 02 May 2018 Planned End Date changed from 1 May 2018 to 1 Nov 2018.